Sigma Healthcare Withdraws from Boots Sale Process
Sigma Healthcare Ltd disclosed that it has terminated its participation in the sale process for the United Kingdom’s Boots Group. The decision was taken immediately after a preliminary review indicated that the prospective acquisition would not satisfy the company’s strategic and capital investment objectives. Consequently, the board determined that the transaction did not align with Sigma’s current strategic priorities or its capital allocation framework.
Market Reaction
Following the announcement, Sigma’s Sydney‑listed shares rose sharply, gaining 8% to close at A$2.85 as of 00:53 GMT.
Strategic Outlook
Despite the withdrawal, Sigma reiterated that international growth remains one of its four key strategic pillars. The company affirmed its ongoing commitment to expanding in its core offshore markets and indicated that it will continue to evaluate acquisitions and investments that deliver long‑term sustainable returns for shareholders.